Nucleophosmin as a candidate prognostic biomarker of ewing's sarcoma revealed by proteomics

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2885-2894

  Kikuta, Kazutaka ^a,e   Tochigi, Naobumi ^b   Shimoda, Tadakazu ^b   Yabe, Hiroki ^e   Morioka, Hideo ^e   Toyama, Yoshiaki ^e   Hosono, Ako ^c   Eppu, Yasuo ^d   Kawai, Akira ^d   Hirohashi, Setsuo ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Diagnosis Pathology Division   (Japan)

^c Pediatric Oncology Division   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; NUCLEOPHOSMIN; THERARUBICIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; BONE BIOPSY; BONE TISSUE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROTEOMICS; SARCOMA, EWING'S; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 65349144856     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1913     Document Type: Article

References (50)

1. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-14.
2. Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997;20:843-6.
3. Diaz MA,Vicent MG, Madero L. High-dose busulfan/ melphalan as conditioning for autologousPBPC transplantation in pediatricpatientswith solid tumors. Bone MarrowTransplant1999;24:1157-9.
4. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children s Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol 2006;24:152-9.
5. Engelhardt M, Zeiser R, Ihorst G, Finke J, Muller CI. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol 2007;133:1-11.
6. McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol 2006; 17:1301-5.
7. Grier HE, Krailo MD,Tarbell NJ, et al. Addition of ifos- famide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
8. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-30.
9. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European In-tergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275-81.
10. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18:4-11.
11. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003;40:276-87.
12. Hayes FA, Thompson EI, Meyer WH, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989;7:208-13.
13. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999;17:180-90.
14. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004;23:8997-9006.
15. Cheung IY, FengY, Danis K, et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007;13: 6978-83.
16. Armengol G,Tarkkanen M,Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. BrJ Cancer1997;75:1403-9.
17. Maurici D, Perez-Atayde A, Grier HE, Baldini N, Serra M, Fletcher JA. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer GenetCytogenet1998;100:106-10.
18. Hattinger CM, Potschger U,Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewingtumours. BrJCancer2002;86:1763-9.
19. Schaefer KL, Eisenacher M, Braun Y, et al. Microar- ray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur JCancer2008;44:699-709.
20. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
21. SueharaY, KondoT, Fujii K, et al. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 2006;6: 4402-9.
22. Chen G, GharibTG,Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A2003;100:13537-42.
23. SueharaY, KondoT, Seki K, et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008;14: 1707-17.
24. OkanoT,KondoT,FujiiK,etal.Proteomicsignature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyro- sine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 2007;13:799-805.
25. Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate 1999;39: 298-304.
26. Tanaka M, Sasaki H, Kino I, SugimuraT,Terada M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res1992;52:3372-7.
27. NozawaY,VanBelzenN,VanderMadeAC,Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178:48-52.
28. ZhangY. TheARF-B23 connection: implications for growth control and cancer treatment. Cell Cycle 2004;3:259-62.
29. Tsui KH, Cheng AJ, Chang PL, PanTL,Yung BY. Association of nucleophosmin/B23 mRNA expres- sion with clinical outcome in patients with bladder car-cinoma. Urology2004;64:839-44.
30. Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996;27:473-81.
31. ShankarAG,AshleyS,CraftAW,PinkertonCR.Out come after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40:141 -7.
32. Urano F, Umezawa A,Yabe H, et al. Molecular analysis of Ewing's sarcoma: another fusion gene, EWS- E1AF, available for diagnosis. Cancer Sci 1998;89: 703 -11.
33. KondoT, Hirohashi S. Application ofhighlysensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer pro-teomics. NatProtoc2006;1:2940-56.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc1958;53:1.
35. CoxDR. Regression models andlifetables. JR Stat Soc 1972;34:187-220.
36. Obata H, UedaT, Kawai A, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007;109: 767-75.
37. Yun JP,Miao J,Chen GG,etal. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 2007;96:477-84.
38. Bacci G,Ferrari S,Bertoni F,etal. Neoadjuvantche- motherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the Istituto Riz-zoli.JClin Oncol 2000;18:885-92.
39. Oberlin O, Deley MC, Bui BN, et al. Prognosticfac-tors in localized Ewing's tumours and peripheral neu-roectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001;85:1646-54.
40. BaillyRA,BosselutR,ZucmanJ,etal.DNA-binding and transcriptional activation properties of the EWS- FLI-1fusion protein resulting from thet(11;22) translo- cation in Ewing sarcoma. Mol Cell Biol 1994;14: 3230-41.
41. Sollazzo MR, Benassi MS, Magagnoli G, et al. In- creasedc- myconcogeneexpressioninEwing'ssarco- ma: correlation with Ki67 proliferation index. Tumori 1999;85:167-73.
42. JavelaudD,PouponMF,WietzerbinJ,BesanconF. Inhibition of constitutive NF-κBactivity suppresses tumorigenicity of Ewing sarcoma EW7 cells. Int J Cancer 2002;98:193-8.
43. Fuchs B, Inwards CY, Janknecht R. Vascular endo- thelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-53.
44. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999;79: 1185-9.
45. deAlavaE,Antonescu CR,PanizoA,etal.Prognos- tic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-92.
46. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
47. Ladanyi M. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biol Ther 2002;1:330-6.
48. Siligan C, Ban J, Bachmaier R, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 2005;24:2512-24.
49. Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003;12:1151-64.
50. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6:493-505.